%0 Journal Article
%T Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
%A Antunes L
%A Mazagatos C
%A Martínez-Baz I
%A Naesens R
%A Borg ML
%A Petrović G
%A Fatukasi T
%A Jancoriene L
%A Machado A
%A Oroszi B
%A Husa P
%A Lazar M
%A Dürrwald R
%A Howard J
%A Melo A
%A Pérez-Gimeno G
%A Castilla J
%A Bernaert E
%A Džiugytė A
%A Makarić ZL
%A Fitzgerald M
%A Mickienė A
%A Gomez V
%A Túri G
%A Součková L
%A Marin A
%A Tolksdorf K
%A Nicolay N
%A Rose AMC
%A  
%J Influenza Other Respir Viruses
%V 18
%N 8
%D 2024 Aug
%M 39145535
%F 5.606
%R 10.1111/irv.13360
%X We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.